C2i Genomics Announces Strategic New Hires to Expand Commercialization of Whole Genome Cancer Detection Platform
C2i Genomics, the world’s first platform for cancer intelligence utilizing whole-genome pattern detection, announces strategic new hires and board appointments to help revolutionize disease monitoring in clinical oncology and therapeutics development. The new team members bring decades of experience from leading pharmaceutical, genomics, and diagnostics companies. Mark Oldroyd has joined as Chief Business Officer, Ravi Kandasamy has joined as Vice President for Research & Development, and Alex Parker has joined the Board of Directors. C2i Genomics also announces that it has joined BloodPAC, a consortium dedicated to accelerating the development and validation of liquid biopsy assays in oncology.
C2i’s cancer intelligence technology applies whole-genome sequencing and artificial intelligence that recognizes patient-specific cancer patterns in very small (just 2mL) blood samples to provide unprecedented acuity in cancer detection – up to 100x more sensitive than competing technologies. This technology also eliminates the need to develop a patient-specific assay, enabling high performance monitoring with reduced complexity and rapid turnaround. In addition to improving cancer patient outcomes, C2i technology can accelerate drug development by providing real time information for oncology clinical trial enrollment and development of highly sensitive and specific surrogate endpoints.
Aiming to bring this breakthrough technology to the clinic and the drug development space faster, C2i Genomics has made three key additions to its team.
Chief Business Officer Mark Oldroyd is focused on expanding the company’s partnerships with pharmaceutical, lab and health technology companies. Mr. Oldroyd brings more than 26 years of experience in biopharma and diagnostics, including business development and commercialization. Before joining C2i, he held multiple leadership roles at Foundation Medicine and Tempus Labs.
Vice President for Research and Development Ravi Kandasamy will be leading genomic assay development activities and CLIA lab operations. Mr. Kandasamy brings nearly a decade of experience leading Discovery, Translational genomics and Biomarker efforts at Bristol-Myers Squibb and GlaxoSmithKline.
Independent Board Member Alex Parker will advise C2i Genomics in developing its commercialization and biopharma strategies. Mr. Parker currently serves as Senior Vice President for Clinical Product Strategy at Thrive Earlier Detection and previously spent more than 7 years at NGS precision oncology innovator Foundation Medicine.
“We’re thrilled to bring on board Mark, Ravi and Alex. The decades of invaluable experience they gained while leading various genomics and diagnostics projects is of enormous importance for C2i and will assure successful commercialization of company’s technology,” said Asaf Zviran, CEO and founder of C2i Genomics. “We’re also excited to join BloodPAC and advance research and development for the entire liquid biopsy industry.”
For companies interested in partnering or using C2i’s cancer intelligence technology or anybody interested in working at C2i, please visit c2i-genomics.com.
About C2i Genomics
Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) whole-genome sequencing to provide 100x more sensitive detection than competing liquid biopsy companies. With a headquarters in NYC and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. The firm is backed by top life sciences investors including Casdin Capital, NFX, and The Mark Foundation for Cancer Research. For more information, please visit c2i-genomics.com.